NCT02649608View on ClinicalTrials.gov

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Parkinson Disease

Interventions

DRUG

0.04 mg Lu AE04621

0.04 mg dose group

DRUG

0.08 mg Lu AE04621

0.08mg dose group

DRUG

0.2 mg Lu AE04621

0.2 mg dose group

DRUG

0.4 mg Lu AE04621

0.4 mg dose group

DRUG

0.6 mg Lu AE04621

0.6 mg dose group

DRUG

0.8 mg Lu AE04621

0.8 mg dose group

DRUG

1.0 mg Lu AE04621

1.0 mg dose group

DRUG

1.2 mg Lu AE04621

1.2 mg dose group

Trial Locations (4)

Unknown

US1251, Hallandale

US1126, Orlando

US1352, Chicago

US1084, Detroit

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY

NCT02649608 - An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients | Biotech Hunter | Biotech Hunter